Literature DB >> 24152786

Epithelial-mesenchymal transition and its regulators are major targets of triple-negative breast cancer.

Ala-Eddin Al Moustafa1.   

Abstract

Triple negative breast cancers (TNBCs) represent a distinct subtype of breast cancers that are associated with early recurrence and an aggressive metastatic progression of the disease and consequently poor outcome. Recently, it was reported that c-Met growth factor receptor is overexpressed in around 52% of TNBCs. On the other hand, it is known that c-Met signaling pathways initiate the epithelial-mesenchymal transition (EMT) phenomenon, which is described as a crucial event during cancer metastasis. Herein, we discuss the association between c-Met and EMT in the TNBC group.

Entities:  

Keywords:  EMT; IGF-1; Leptin; breast cancer; c-Met; metastasis & cancer mortality; triple negative

Mesh：

Substances：

Year:  2013        PMID： 24152786      PMCID： PMC3903687          DOI： 10.4161/cam.26728

Source DB:  PubMed          Journal:  Cell Adh Migr        ISSN： 1933-6918            Impact factor:   3.405


  18 in total

1.  Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors.

Authors:  Idris Tolgay Ocal; Marisa Dolled-Filhart; Thomas G D'Aquila; Robert L Camp; David L Rimm
Journal:  Cancer       Date:  2003-04-15       Impact factor: 6.860

2.  Efficacy of a leptin receptor antagonist peptide in a mouse model of triple-negative breast cancer.

Authors:  Laszlo Otvos; Ilona Kovalszky; Mirko Riolfi; Rita Ferla; Julia Olah; Andras Sztodola; Kaushik Nama; Annamaria Molino; Quirino Piubello; John D Wade; Eva Surmacz
Journal:  Eur J Cancer       Date:  2011-02-23       Impact factor: 9.162

3.  Osthole suppresses hepatocyte growth factor (HGF)-induced epithelial-mesenchymal transition via repression of the c-Met/Akt/mTOR pathway in human breast cancer cells.

Authors:  Chao-Ming Hung; Daih-Huang Kuo; Chun-Hung Chou; Yen-Chao Su; Chi-Tang Ho; Tzong-Der Way
Journal:  J Agric Food Chem       Date:  2011-08-08       Impact factor: 5.279

4.  c-met tyrosine kinase receptor expression is associated with abnormal beta-catenin expression and favourable prognostic factors in invasive breast carcinoma.

Authors:  L Nakopoulou; H Gakiopoulou; A Keramopoulos; I Giannopoulou; P Athanassiadou; J Mavrommatis; P S Davaris
Journal:  Histopathology       Date:  2000-04       Impact factor: 5.087

Review 5.  Leptin signaling in breast cancer: an overview.

Authors:  Donatella Cirillo; Anna Maria Rachiglio; Raffaele la Montagna; Antonio Giordano; Nicola Normanno
Journal:  J Cell Biochem       Date:  2008-11-01       Impact factor: 4.429

6.  Favorable changes in serum estrogens and other biologic factors after weight loss in breast cancer survivors who are overweight or obese.

Authors:  Cheryl L Rock; Chetna Pande; Shirley W Flatt; Carl Ying; Bilge Pakiz; Barbara A Parker; Kathryn Williams; Wayne A Bardwell; Dennis D Heath; Jeanne F Nichols
Journal:  Clin Breast Cancer       Date:  2013-01-29       Impact factor: 3.225

Review 7.  Src signaling in cancer invasion.

Authors:  Marcello Guarino
Journal:  J Cell Physiol       Date:  2010-04       Impact factor: 6.384

Review 8.  EGF-receptor signaling and epithelial-mesenchymal transition in human carcinomas.

Authors:  Ala-Eddin Al Moustafa; Amal Achkhar; Amber Yasmeen
Journal:  Front Biosci (Schol Ed)       Date:  2012-01-01

9.  Metabolic syndrome and triple-negative breast cancer: a new paradigm.

Authors:  Andrew A Davis; Virginia G Kaklamani
Journal:  Int J Breast Cancer       Date:  2011-10-15

10.  High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer.

Authors:  F Zagouri; Z Bago-Horvath; F Rössler; A Brandstetter; R Bartsch; C A Papadimitriou; C Dimitrakakis; A Tsigginou; I Papaspyrou; A Giannos; M-A Dimopoulos; M Filipits
Journal:  Br J Cancer       Date:  2013-02-19       Impact factor: 7.640
View more
  11 in total

1.  High level of FHL2 exacerbates the outcome of non-small cell lung cancer (NSCLC) patients and the malignant phenotype in NSCLC cells.

Authors:  Na Li; Ling Xu; Ji Zhang; Yongyu Liu
Journal:  Int J Exp Pathol       Date:  2022-04-02       Impact factor: 2.793

2.  Activation of GPER suppresses epithelial mesenchymal transition of triple negative breast cancer cells via NF-κB signals.

Authors:  Zhuo-Jia Chen; Wei Wei; Guan-Min Jiang; Hao Liu; Wei-Dong Wei; Xiangling Yang; Ying-Min Wu; Huanliang Liu; Chris K C Wong; Jun Du; Hong-Sheng Wang
Journal:  Mol Oncol       Date:  2016-01-18       Impact factor: 6.603

3.  Litchi Seed Aqueous Extracts play a role in suppression of epithelial-mesenchymal transition, invasion and migration in breast cancer cells.

Authors:  Yanling Ma; Fei Yan; Wujie Wei; Jie Deng; Li Li; Li Liu; Jianhai Sun
Journal:  Cell Cycle       Date:  2020-01-10       Impact factor: 4.534

Review 4.  Roles of c-Met and RON kinases in tumor progression and their potential as therapeutic targets.

Authors:  Katherine Chang; Anand Karnad; Shujie Zhao; James W Freeman
Journal:  Oncotarget       Date:  2015-02-28

5.  Novel function of THEMIS2 in the enhancement of cancer stemness and chemoresistance by releasing PTP1B from MET.

Authors:  Wei-Chieh Huang; Jia-Hau Yen; Yu-Wen Sung; Shiao-Lin Tung; Po-Ming Chen; Pei-Yi Chu; Ya-Chi Shih; Hsiang-Cheng Chi; Yi-Ching Huang; Shih-Jei Huang; Lu-Hai Wang
Journal:  Oncogene       Date:  2022-01-01       Impact factor: 9.867

6.  A novel screening approach comparing kinase activity of small molecule inhibitors with similar molecular structures and distinct biologic effects in triple-negative breast cancer to identify targetable signaling pathways.

Authors:  Margarite D Matossian; Hope E Burks; Steven Elliott; Van T Hoang; William J Zuercher; Carrow Wells; David H Drewry; Nirav Kapadia; Tiffany Chang; Thomas Yan; Gabrielle O Windsor; Khoa Nguyen; Fang Fang; Kenneth P Nephew; Aaron Buechlein; Douglas B Rusch; Rachel A Sabol; Deniz A Ucar; Jovanny Zabaleta; Lucio Miele; Bruce A Bunnell; Bridgette M Collins-Burow; Matthew E Burow
Journal:  Anticancer Drugs       Date:  2020-09       Impact factor: 2.389

7.  Differential expression and clinical significance of epithelial-mesenchymal transition markers among different histological types of triple-negative breast cancer.

Authors:  Shuling Zhou; Xiangjie Sun; Lin Yu; Ruoji Zhou; Anqi Li; Ming Li; Wentao Yang
Journal:  J Cancer       Date:  2018-01-05       Impact factor: 4.207

8.  Epithelial-Mesenchymal Transition Markers in Breast Cancer and Pathological Responseafter Neoadjuvant Chemotherapy.

Authors:  Shaimaa Elzamly; Nabeel Badri; Osvaldo Padilla; Alok Kumar Dwivedi; Luis A Alvarado; Matthew Hamilton; Nabih Diab; Crosby Rock; Ahmed Elfar; Marwa Teleb; Luis Sanchez; Zeina Nahleh
Journal:  Breast Cancer (Auckl)       Date:  2018-08-01

9.  DCST1-AS1 Promotes TGF-β-Induced Epithelial-Mesenchymal Transition and Enhances Chemoresistance in Triple-Negative Breast Cancer Cells via ANXA1.

Authors:  Li Tang; Yuli Chen; Huanhuan Chen; Pan Jiang; Linping Yan; Dongping Mo; Xun Tang; Feng Yan
Journal:  Front Oncol       Date:  2020-03-12       Impact factor: 6.244

10.  Dihydrotanshinone-I modulates Epithelial Mesenchymal Transition (EMT) Thereby Impairing Migration and Clonogenicity of Triple Negative Breast Cancer Cells.

Authors:  Akanksha Kashyap; Sheikh Mohammad Umar; Arundhathi Dev J R; Chandra Prakash Prasad
Journal:  Asian Pac J Cancer Prev       Date:  2021-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.